Protagonist Therapeutics (PTGX) Price & Analysis

Compare

733 Followers

PTGX Stock Chart & Stats

$96.75

-$0.87(-2.26%)

At close: Jan 08 4:00 PM EST

$96.75

-$0.87(-2.26%)

Day’s Range― - ―

52-Week Range$39.60 - $98.32

Previous CloseN/A

Volume120.35K

Average Volume (3M)633.14K

Market Cap

$6.17B

Enterprise Value$6.06B

Total Cash (Recent Filing)$567.36M

Total Debt (Recent Filing)$10.32M

Price to Earnings (P/E)―

Beta0.16

Next Earnings

May 06, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.69

Shares Outstanding63,808,716

10 Day Avg. Volume752,267

30 Day Avg. Volume633,137

Financial Highlights & Ratios

PEG Ratio0.29

Price to Book (P/B)9.03

Price to Sales (P/S)120.66

P/FCF Ratio99.01

Enterprise Value/Market Cap0.98

Enterprise Value/Revenue131.59

Enterprise Value/Gross Profit132.68

Enterprise Value/Ebitda-42.31

Forecast

1Y Price Target

$104.67

Price Target Upside8.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)3.62

Revenue Forecast (FY)$471.93M

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsRusfertide's Phase III program demonstrated durable control of hematocrit with reduced reliance on phlebotomy and strong physician interest, strengthening the drug's case for regulatory approval and commercial uptake.

Obesity Portfolio And Partnership PotentialA developing obesity portfolio that includes oral and injectable candidates with promising preclinical weight-loss profiles may attract partnership or acquisition interest and accelerate development paths.

Technology Platform And Internal Pipeline QualityInternal programs that leverage a proven technology platform and well-understood biological mechanisms could emerge as best-in-class assets, increasing their appeal to partners and prescribers.

Bears Say

Analyst/report CredibilityDisclosure of business ties between the research firm and companies it covers raises concerns about report objectivity and may undermine investor confidence in analyst conclusions.

Deal Terms And Near-term Financial ObligationsOpting out of a partnered program could trigger substantial opt-out and milestone payments, raising near-term financial obligations and pressure on cash management.

Pipeline Transparency And Strategic ClarityPossible downplaying of a new hepcidin candidate due to an existing collaboration creates uncertainty around the asset's development path and the company's strategic disclosures.

Protagonist Therapeutics News

Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)

WSW, NY, March 5th, 2026, FinanceWire As Washington pushes cheaper medicines through TrumpRx, Mark Cuban challenges the pharmaceutical...

12d ago

AZN

IBO

Protagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $95 from $65 and keeps a...

14d ago

PTGX

Protagonist Therapeutics price target raised to $100 from $86 at Wedbush

Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $100 from $86 and keeps an Outperform...

15d ago

TAK

PTGX

Takeda, Protagonist announce FDA acceptance of rusfertide new drug application

Takeda (TAK) and Protagonist Therapeutics (PTGX) announced that the FDA accepted the new drug application and granted priority...

15d ago

TAK

PTGX

Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan

JPMorgan analyst Brian Cheng raised the firm’s price target on Protagonist Therapeutics (PTGX) to $95 from $93 and...

18d ago

PTGX

Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen

TD Cowen analyst Tara Bancroft raised the firm’s price target on Protagonist Therapeutics (PTGX) to $100 from $90...

19d ago

PTGX

Protagonist Therapeutics price target raised to $112 from $102 at Citizens

Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $112 from $102 and keeps an Outperform...

19d ago

PTGX

Protagonist Therapeutics price target raised to $113 from $108 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $113 from $108 and keeps an Overweight...

19d ago

PTGX

Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines

Protagonist Therapeutics Inc (PTGX) has disclosed a new risk, in the Regulation category. Disruptions at the FDA and...

19d ago

PTGX

Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on PTGX stock, giving a Buy rating today....

19d ago

PTGX

Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target

Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Protagonist Therapeutics, with a price target of...

20d ago

PTGX

Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $117 from $80 and keeps a...

2M ago

PTGX

Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating

Analyst Yun Zhong of Wedbush maintained a Buy rating on Protagonist Therapeutics, boosting the price target to $86.00....

2M ago

PTGX

Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships

Protagonist Therapeutics ( ($PTGX) ) has issued an update. On January 12, 2026, Protagonist Therapeutics released an updated...

2M ago

PTGX

PTGX FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?

Protagonist Therapeutics lowest stock price was $39.60 and its highest was $98.32 in the past 12 months.

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is $6.17B.

When is Protagonist Therapeutics’s upcoming earnings report date?

Protagonist Therapeutics’s upcoming earnings report date is May 06, 2026 which is in 50 days.

How were Protagonist Therapeutics’s earnings last quarter?

Protagonist Therapeutics released its earnings results on Feb 25, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.567 by -$0.123.

Is Protagonist Therapeutics overvalued?

According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics does not currently pay dividends.

What is Protagonist Therapeutics’s EPS estimate?

Protagonist Therapeutics’s EPS estimate is -0.45.

How many shares outstanding does Protagonist Therapeutics have?

Protagonist Therapeutics has 63,808,716 shares outstanding.

What happened to Protagonist Therapeutics’s price movement after its last earnings report?

Protagonist Therapeutics reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.567. Following the earnings report the stock price went up 1.481%.

Which hedge fund is a major shareholder of Protagonist Therapeutics?

Currently, no hedge funds are holding shares in PTGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-19.89%

Trailing 12-Months

Asset Growth

-10.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics (PTGX) Earnings & Revenues

Historic Earnings Reports

PTGX Stock 12 Month Forecast

Average Price Target

$104.67

▲(8.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","77":"$77","118":"$118","56.5":"$56.5","97.5":"$97.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":117,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$117.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,56.5,77,97.5,118],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.24,95.99076923076923,97.74153846153845,99.49230769230769,101.24307692307691,102.99384615384615,104.74461538461539,106.49538461538461,108.24615384615385,109.99692307692308,111.7476923076923,113.49846153846154,115.24923076923076,{"y":117,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.24,95.04230769230769,95.84461538461538,96.64692307692307,97.44923076923077,98.25153846153846,99.05384615384615,99.85615384615384,100.65846153846154,101.46076923076923,102.26307692307692,103.06538461538462,103.86769230769231,{"y":104.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.24,94.29846153846154,94.35692307692307,94.41538461538461,94.47384615384615,94.53230769230768,94.59076923076923,94.64923076923077,94.70769230769231,94.76615384615384,94.82461538461538,94.88307692307693,94.94153846153846,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.24,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >